Industries > Pharma > Global Oncology Pricing, Reimbursement & Market Access 2019-2029

Global Oncology Pricing, Reimbursement & Market Access 2019-2029

US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China

PUBLISHED: 10 September 2019
PAGES: 292
PRODUCT CODE: PHA0522
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0522 Categories: , Tags: , , , , ,

The global oncology pricing, reimbursement and market access report provides analysis and evaluation of the current and prospective economic burden of cancer treatment in the US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China. This report also outlines historical and current healthcare status for the selected markets with respect to expenditures along with the healthcare system that governs medical access.

In this report, we provide comprehensive view on some of the trends for top-seller oncology drugs including payer’s perspective on cancer outcomes, impact of these high cost drugs, standard guidelines preferred for different cancers, availability and costs of oncology therapeutics and complexity in cancer treatments as well as epidemiology of different cancer types.

How this report will benefit you
In this brand new 292-page report you will receive 98 charts– all unavailable elsewhere.

The 292-page report provides clear detailed insight into the global oncology pricing, reimbursement & market access. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Key questions answered by this report:
• Factors Affecting Pricing and Reimbursement Decision
• Pricing Negotiations and Discounts
• Reimbursement Policies
• Role of HEOR and Economic Value Planning
• Drug Patent Expiry and Effects on Pricing
• Cost-Effectiveness Analysis

• This report discusses healthcare system, pricing & reimbursement process, HTA, oncology cost of treatment, payer insights, healthcare expenditure, health coverage, key formularies, role of pharmacists, regulatory & approval process for these countries:
• United States
• Canada
• Germany
• France
• UK
• Italy
• Spain
• Japan
• Australia
• Brazil
• Russia
• India
• China

• Discussion on parallel import and its impact in the US and Europe.

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Oncology Pricing, Reimbursement and Market Access. You find data, trends and predictions.

Buy our report today Global Oncology Pricing, Reimbursement & Market Access 2019-2029: US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Oncology Pricing, Reimbursement & Market Access 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Oncology Pricing, Reimbursement & Market Access 2019-2029


Latest Pharma news

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

READ

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

READ

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

READ

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

READ